Design of 8-mer Peptides that Block Clostridioides difficile Toxin A in Intestinal Cells

Clostridioides difficile (C. diff.) is a bacterium that causes severe diarrhea and inflammation of the colon. The pathogenicity of C. diff. infection is derived from two major toxins, toxins A (TcdA) and B (TcdB). Peptide inhibitors that can be delivered to the gut to inactivate these toxins are an attractive therapeutic strategy. In this work, we present a new approach that combines a peptide binding design algorithm (PepBD), molecular-level simulations, rapid screening of candidate peptides for toxin binding, a primary human cell-based assay, and surface plasmon resonance (SPR) measurements to develop peptide inhibitors that block the glucosyltransferase activity of TcdA by targeting its glucosyltransferase domain (GTD). Using PepBD and explicit-solvent molecular dynamics simulations, we identified seven candidate peptides, SA1-SA7. These peptides were selected for specific TcdA GTD binding through a custom solid-phase peptide screening system, which eliminated the weaker inhibitors SA5-SA7. The efficacies of SA1-SA4 were then tested using a trans-epithelial electrical resistance (TEER) assay on monolayers of the human gut epithelial culture model. One peptide, SA1, was found to block TcdA toxicity in primary-derived human jejunum (small intestinal) and colon (large intestinal) epithelial cells. SA1 bound TcdA with a KD of 56.1 ± 29.8 nM as measured by surface plasmon resonance (SPR). Significance Statement Infections by Clostridioides difficile, a bacterium that targets the large intestine (colon), impact a significant number of people worldwide. Bacterial colonization is mediated by two exotoxins: toxins A and B. Short peptides that can inhibit the biocatalytic activity of these toxins represent a promising strategy to prevent and treat C. diff. infection. We describe an approach that combines a Peptide Binding Design (PepBD) algorithm, molecular-level simulations, a rapid screening assay to evaluate peptide:toxin binding, a primary human cell-based assay, and surface plasmon resonance (SPR) measurements to develop peptide inhibitors that block Toxin A in small intestinal and colon epithelial cells. Importantly, our designed peptide, SA1, bound toxin A with nanomolar affinity and blocked toxicity in colon cells.

[1]  C. Hall,et al.  Computational Design and Experimental Validation of ACE2-Derived Peptides as SARS-CoV-2 Receptor Binding Domain Inhibitors , 2022, The journal of physical chemistry. B.

[2]  S. Magness,et al.  A Planar Culture Model of Human Absorptive Enterocytes Reveals Metformin Increases Fatty Acid Oxidation and Export , 2022, Cellular and molecular gastroenterology and hepatology.

[3]  C. Hall,et al.  De novo discovery of peptide-based affinity ligands for the fab fragment of human immunoglobulin G. , 2022, Journal of chromatography. A.

[4]  Nathan Crook,et al.  In Silico Identification and Experimental Validation of Peptide-Based Inhibitors Targeting Clostridium difficile Toxin A. , 2021, ACS chemical biology.

[5]  J. Woosley,et al.  A Proximal-to-Distal Survey of Healthy Adult Human Small Intestine and Colon Epithelium by Single-Cell Transcriptomics , 2021, bioRxiv.

[6]  M. Daniele,et al.  Engineering Next Generation Cyclized Peptide Ligands for Light‐Controlled Capture and Release of Therapeutic Proteins , 2021, Advanced Functional Materials.

[7]  R. Carbonell,et al.  Novel peptide ligands for antibody purification provide superior clearance of host cell protein impurities. , 2020, Journal of chromatography. A.

[8]  Mikael Olsson.  Struct , 2019, C# 8 Quick Syntax Reference.

[9]  R. Naik,et al.  In-Silico Discovery and Validation of Neuropeptide Y Binding Peptides for Sensors. , 2019, The journal of physical chemistry. B.

[10]  Kevin N. Day,et al.  Discovery and evaluation of peptide ligands for selective adsorption and release of Cas9 nuclease on solid substrates. , 2019, Bioconjugate chemistry.

[11]  Miriam H. Huntley,et al.  Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. , 2019, The New England journal of medicine.

[12]  X. Xie,et al.  PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance , 2019, Molecules.

[13]  Lan Huang,et al.  Structure of the full-length Clostridium difficile toxin B , 2019, Nature Structural & Molecular Biology.

[14]  A. San-Miguel,et al.  Affordable Microfluidic Bead-Sorting Platform for Automated Selection of Porous Particles Functionalized with Bioactive Compounds , 2019, Scientific Reports.

[15]  S. Whelan,et al.  Sulfated glycosaminoglycans and low-density lipoprotein receptor contribute to Clostridium difficile toxin A entry into cells , 2019, Nature Microbiology.

[16]  H. Nair,et al.  Global burden of Clostridium difficile infections: a systematic review and meta-analysis , 2018, Journal of global health.

[17]  J. Parker,et al.  A Monolayer of Primary Colonic Epithelium Generated on a Scaffold with a Gradient of Stiffness for Drug Transport Studies. , 2018, Analytical chemistry.

[18]  Joseph M Slocik,et al.  Advancing Peptide-Based Biorecognition Elements for Biosensors Using in-Silico Evolution. , 2018, ACS sensors.

[19]  Mohammad Rahbar,et al.  Clostridium difficile infection: a review , 2018, Reviews in Medical Microbiology.

[20]  K. Kinoshita.  [Preclinical and clinical properties of Bezlotoxumab (ZINPLAVA® 25 mg/mL concentrate for solution for infusion), novel therapeutic agent for Clostridium difficile infection]. , 2018, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[21]  Brendan J. Kelly,et al.  Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection , 2018, Chest.

[22]  N. Marzella,et al.  Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection. , 2017, P & T : a peer-reviewed journal for formulary management.

[23]  K. Acharya,et al.  The structure of the S-layer of Clostridium difficile , 2017, Journal of Cell Communication and Signaling.

[24]  C. Hall,et al.  Extended Concerted Rotation Technique Enhances the Sampling Efficiency of the Computational Peptide-Design Algorithm. , 2017, Journal of chemical theory and computation.

[25]  Klaus Aktories,et al.  Clostridium difficile Toxin Biology. , 2017, Annual review of microbiology.

[26]  C. Edmiston,et al.  Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update. , 2017, Surgery.

[27]  Colleen E. Price,et al.  Development of a non-radiolabeled glucosyltransferase activity assay for C. difficile toxin A and B using ultra performance liquid chromatography. , 2017, Journal of chromatography. A.

[28]  Angela Proctor,et al.  Self-renewing Monolayer of Primary Colonic or Rectal Epithelial Cells , 2017, Cellular and molecular gastroenterology and hepatology.

[29]  Joshua N. Leonard,et al.  Adding energy minimization strategy to peptide‐design algorithm enables better search for RNA‐binding peptides: Redesigned λ N peptide binds boxB RNA , 2016, J. Comput. Chem..

[30]  C. Hall,et al.  Simulation study of the ability of a computationally‐designed peptide to recognize target tRNALys3 and other decoy tRNAs , 2016, Protein science : a publication of the Protein Society.

[31]  Peter T. McKenney,et al.  Clostridium difficile colitis: pathogenesis and host defence , 2016, Nature Reviews Microbiology.

[32]  Xingqing Xiao,et al.  Introducing folding stability into the score function for computational design of RNA‐binding peptides boosts the probability of success , 2016, Proteins.

[33]  D. Giedroc,et al.  Crystal structure of Clostridium difficile toxin A , 2016, Nature Microbiology.

[34]  Nora C. Toussaint,et al.  Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole. , 2015, The Journal of infectious diseases.

[35]  D. Duffy,et al.  Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool , 2015, Journal of Clinical Microbiology.

[36]  D. Leffler,et al.  Clostridium difficile infection. , 2015, The New England journal of medicine.

[37]  Lisa G Winston,et al.  Burden of Clostridium difficile Infection in the United States , 2015 .

[38]  R. Carbonell,et al.  Dynamic and equilibrium performance of sensors based on short peptide ligands for affinity adsorption of human IgG using surface plasmon resonance. , 2014, Biosensors & bioelectronics.

[39]  C. Hall,et al.  The design of a peptide sequence to inhibit HIV replication: a search algorithm combining Monte Carlo and self-consistent mean field techniques , 2014, Journal of biomolecular structure & dynamics.

[40]  T. Riley,et al.  Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. , 2014, The Journal of antimicrobial chemotherapy.

[41]  C. Hall,et al.  Amino Acid Signature Enables Proteins to Recognize Modified tRNA , 2014, Biochemistry.

[42]  J. Tanha,et al.  Structural Basis for Antibody Recognition in the Receptor-binding Domains of Toxins A and B from Clostridium difficile* , 2013, The Journal of Biological Chemistry.

[43]  A. Lisitsa,et al.  Kinetic and thermodynamic analysis of dimerization inhibitors binding to HIV protease monomers by surface plasmon resonance , 2012, Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry.

[44]  A. Feig,et al.  Peptide inhibitors targeting Clostridium difficile toxins A and B. , 2010, ACS chemical biology.

[45]  Nigel P. Minton,et al.  The role of toxin A and toxin B in Clostridium difficile infection , 2010, Nature.

[46]  C. Stafford,et al.  Quantification of the binding affinity of a specific hydroxyapatite binding peptide. , 2010, Biomaterials.

[47]  L. Gonzales.  Clostridium difficile , 2010, Methods in Molecular Biology™.

[48]  C. Karp.  Pathogenesis and Host Defenses , 2009 .

[49]  Mark H. Wilcox,et al.  Clostridium difficile infection: new developments in epidemiology and pathogenesis , 2009, Nature Reviews Microbiology.

[50]  Dmitri I Svergun,et al.  Structural insights into the molecular organization of the S‐layer from Clostridium difficile , 2009, Molecular microbiology.

[51]  Julian I. Rood,et al.  Toxin B is essential for virulence of Clostridium difficile , 2009, Nature.

[52]  G. Schulz,et al.  Conformational changes and reaction of clostridial glycosylating toxins. , 2008, Journal of molecular biology.

[53]  Chih-Kung Lee,et al.  Determination of Binding Constant and Stoichiometry for Antibody-Antigen Interaction with Surface Plasmon Resonance , 2006 .

[54]  K. Ng,et al.  Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  A. Feig,et al.  Fluorescent analogs of UDP-glucose and their use in characterizing substrate binding by toxin A from Clostridium difficile. , 2002, European journal of biochemistry.

[56]  D. Bobak,et al.  Clostridium difficile Toxins A and B Are Cation-dependent UDP-glucose Hydrolases with Differing Catalytic Activities* , 1998, The Journal of Biological Chemistry.

[57]  S. Jakes,et al.  Determination of receptor-ligand kinetic and equilibrium binding constants using surface plasmon resonance: application to the lck SH2 domain and phosphotyrosyl peptides. , 1995, Journal of medicinal chemistry.

[58]  B. Malomed,et al.  A new form of liquid matter: Quantum droplets , 2020, Frontiers of Physics.

[59]  D. Altschuh,et al.  Determination of kinetic constants for the interaction between a monoclonal antibody and peptides using surface plasmon resonance. , 1992, Biochemistry.

[60]  R. Shulman,et al.  NMR measurements of in vivo myocardial glycogen metabolism. , 1988, The Journal of biological chemistry.